Updated on Hormone Replacement Therapy (HRT): What the New Research Actually Says
Hormone replacement therapy (HRT) has been one of the most misunderstood areas of women’s health over the past two decades.
For years, many women were told that estrogen therapy significantly increased the risk of breast cancer, heart disease, and stroke, according to the Women’s Health Initiative, and millions stopped treatment almost overnight. But the science behind those warnings has since been reevaluated, and our understanding of hormone therapy has changed dramatically.
Recently, the U.S. Food and Drug Administration (FDA) announced that it will remove black-box warnings from many menopausal hormone therapies, reversing a regulatory decision that has shaped clinical practice since the early 2000s. This decision reflects a growing recognition that the original interpretation of the risks was incomplete and, in some cases, misleading.
Understanding how we arrived here requires revisiting the landmark research that changed menopause care and examining what we now know.
The Women’s Health Initiative: The Study That Changed Everything
In the late 1990s and early 2000s, the Women’s Health Initiative (WHI) became the most influential study in menopause medicine.
The WHI was a large randomized controlled trial designed to evaluate whether hormone therapy could prevent chronic disease, particularly cardiovascular disease and osteoporosis, in postmenopausal women. The study enrolled more than 160,000 women and tested two major hormone regimens:
Estrogen + progestin therapy (for women with a uterus)
Estrogen-only therapy (for women who had undergone a hysterectomy)
In 2002, the WHI investigators halted the estrogen-progestin arm of the study early after observing increased rates of:
Breast cancer
Stroke
Venous thromboembolism
Coronary heart disease
The findings received intense media coverage and led to the immediate conclusion that hormone therapy was dangerous. Prescriptions dropped dramatically worldwide, and in 2003, the FDA required black box warnings on all menopausal hormone therapies, the most serious safety label used for medications.
Within two years, hormone therapy prescriptions in the United States declined by more than 60%.
Why the Original Interpretation Was Flawed
Over the last two decades, reanalysis of the WHI data and numerous follow-up studies have revealed several key methodological issues that dramatically changed the interpretation of risk.
1. The Study Population Was Much Older Than Typical HRT Patients
The average age of women in the WHI trial was 63 years, and many participants were more than 10 years past menopause. However, most women who begin hormone therapy clinically start between the ages of 45 and 55, often during the perimenopausal transition. Later analyses showed that risks differed dramatically depending on when therapy was initiated. This led to the development of the “timing hypothesis.”
The ‘timing hypothesis’ proposes that starting hormone therapy near menopause may be neutral or beneficial for cardiovascular health and that starting therapy many years after menopause may increase cardiovascular risk.
Reanalysis of WHI data demonstrated that women who started estrogen therapy before age 60 or within 10 years of menopause had substantially lower cardiovascular risk compared with older participants (Manson et al., 2013).
2. The Hormone Formulation Used in the Study Was Outdated
The WHI trial used a specific formulation of conjugated equine estrogens (CEE) and Medroxyprogesterone acetate (MPA). These are older synthetic hormones that differ from many modern therapies used today.
Contemporary hormone therapy often includes safer and more absorbable forms of hormones, such as:
Transdermal estradiol patches
Micronized progesterone
Lower-dose formulations
Emerging research suggests that transdermal estrogen may carry a lower risk of blood clots and stroke compared with oral formulations because it bypasses first-pass liver metabolism (Canonico et al., 2007). However, these newer regimens were not evaluated in the original WHI trial.
3. Relative Risk Was Misinterpreted
One of the most widely cited results from the WHI was a 26% increase in breast cancer risk among women using combined estrogen-progestin therapy. But the absolute numbers tell a more nuanced story. The increase represented 8 additional cases of breast cancer per 10,000 women per year. While statistically significant, the relative risk framing dramatically amplified public perception of danger. For comparison, lifestyle factors such as obesity and alcohol consumption carry comparable or greater breast cancer risk (Collaborative Group on Hormonal Factors in Breast Cancer, 2019).
What Follow-Up Research Has Shown
Long-term follow-up studies of WHI participants and newer observational cohorts have significantly reshaped how hormone therapy is viewed. Several major conclusions have emerged.
1. Hormone Therapy Is the Most Effective Treatment for Menopause Symptoms
There is strong consensus among major medical organizations that estrogen therapy remains the most effective treatment for vasomotor symptoms, including:
Hot flashes
Night sweats
Sleep disruption
Mood instability
Estrogen therapy can reduce hot flash frequency by 75–90% in many women (North American Menopause Society, 2022).
2. Bone Health Benefits Are Clear
Estrogen plays a central role in bone metabolism. Hormone therapy significantly reduces the risk of osteoporosis, vertebral fractures, and hip fractures. WHI data demonstrated approximately a 30–35% reduction in fracture risk among women using estrogen therapy (Cauley et al., 2003).
3. Cardiovascular Effects Depend on Age and Timing
Modern analyses show that cardiovascular outcomes vary depending on when therapy begins. Women initiating therapy under age 60 and within 10 years of menopause appear to have neutral or modestly favorable cardiovascular outcomes compared with older women starting therapy later (Manson et al., 2013).
4. Breast Cancer Risk Is Complex and Depends on Therapy Type
Research suggests that breast cancer risk varies depending on duration of therapy, estrogen-only vs combined therapy and type of progesterone used. Estrogen-only therapy in women who have had a hysterectomy did not show increased breast cancer risk in WHI follow-up analyses and may have slightly reduced risk (Anderson et al., 2012). Combined estrogen-progestin therapy does show a small increase in risk with long-term use, particularly beyond 5 years.
Why the FDA Is Removing Black Box Warnings
Given the evolving evidence, the FDA recently announced plans to remove black box warnings from many menopausal hormone therapies. Black box warnings are typically reserved for medications with clear, severe safety concerns across large populations. Experts have increasingly argued that applying this label to all hormone therapy products was scientifically inappropriate, particularly given the variability in formulations and patient populations. The change may improve access for women who suffer from severe menopausal symptoms but have avoided therapy due to safety fears.
However, researchers emphasize that hormone therapy is not a universal anti-aging treatment, and claims that it broadly prevents diseases such as Alzheimer’s or extends longevity remain unsupported.
Who Should and Should Not Use Hormone Therapy
Hormone therapy can be appropriate for many women, but individual risk factors must be considered.
Women who generally should avoid systemic hormone therapy include those with:
Personal history of breast cancer
Estrogen-sensitive cancers
Prior venous thromboembolism
Uncontrolled cardiovascular disease
Additionally, women with a uterus must use combined estrogen and progesterone therapy because estrogen alone increases the risk of endometrial cancer.
The Future of Menopause Medicine
The story of hormone therapy highlights a broader issue in medicine: how early interpretations of research can shape clinical practice for decades. The WHI study was groundbreaking, but its findings were overgeneralized and misunderstood, leading to widespread fear and undertreatment of menopausal symptoms. Today, clinicians recognize that hormone therapy must be personalized, taking into account:
Age
Time since menopause
Cardiovascular risk
Cancer history
Delivery method and dosage
Researchers also emphasize the need for new large-scale studies using modern hormone formulations, as much of the current data still comes from research conducted more than two decades ago.
The Bottom Line
Hormone replacement therapy is neither the dangerous therapy it was once portrayed to be nor the “fountain of youth” some proponents claim.
What the evidence now shows is far more nuanced:
HRT remains one of the most effective treatments for menopausal symptoms (but depends on dose, timing, and form; hormone pellets are not for everyone)
Risks depend heavily on timing, formulation, and individual health history
Earlier research overstated risks for many women, particularly those starting therapy near menopause
Modern therapies may have different safety profiles than older formulations
As menopause research continues to evolve, the most important takeaway is this: women deserve individualized care and accurate information when making decisions about their health during this stage of life.
The good news is that we can test for and support not just hormones but also the entire biochemical steroid pathways that influence and support our sex hormones. At present, functional medicine is rising and shining in this area of health because, if HRT is not a good fit for you, or you would rather support hormones in a more gentle way, botanicals and foundational nutrients or minerals can address all of these areas of health.
Who you consult to help you with your hormones will greatly determine your outcome, and I want to highlight that it isn’t always about replacing hormones, but about supporting a system so the transition is easier for women. It isn’t always just about estrogen or just about progesterone, but the RELATIONSHIP between all of the hormones!
If you cannot find a provider that offers appropriate testing for your hormones (when your blood, saliva, or urine is collected matters!), covering everything in between that matters, or just wants to put you on their “Magic hormone formula” that seems too good to be true, let’s talk!
Here to empower you with the knowledge of health,
Dr. Meg Holpuch
Disclaimer: The information provided on this blog is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The content shared here is not meant to replace or supersede the guidance or recommendations of your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your diet, exercise routine, supplement regimen, or overall health plan. Your health and well-being are unique, and decisions regarding your care should always be made in consultation with your trusted healthcare provider.
References
Anderson GL et al. (2012). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. https://jamanetwork.com/journals/jama/fullarticle/1105218
Canonico M et al. (2007). Postmenopausal hormone therapy and risk of venous thromboembolism. BMJ. https://www.bmj.com/content/336/7655/1227
Cauley JA et al. (2003). Effects of estrogen plus progestin on risk of fracture. JAMA. https://jamanetwork.com/journals/jama/fullarticle/197025
Collaborative Group on Hormonal Factors in Breast Cancer (2019). Menopausal hormone therapy and breast cancer risk. Lancet. https://www.thelancet.com/article/S0140-6736(19)31709-X/fulltext
Manson JE et al. (2013). Menopausal hormone therapy and long-term outcomes. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1211731
North American Menopause Society (2022). The 2022 hormone therapy position statement. https://www.menopause.org
Rossouw JE et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. https://jamanetwork.com/journals/jama/fullarticle/195120
Lewis T., Young L. (2025). FDA removes black box warnings from menopause hormone therapy. Scientific American.
